title: Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology.
abstract: Lewy bodies, alpha-synuclein (alpha-syn) immunopositive intracellular deposits, are the pathological hallmark of Parkinson's disease (PD). Interestingly, Lewybody-like structures have been identified in fetal tissue grafts about one decade after transplantation into the striatum of PD patients. One possible explanation for the accelerated deposition of alpha-syn in the graft is that the aggregation of alpha-syn from the host tissue to the graft is spread by a prion disease-like mechanism. We discuss here an in vitro model which might recapitulate some aspects of disease propagation in PD. We found here that in vitro-generated alpha-syn oligomers induce transmembrane seeding of alpha-syn aggregation in a dose- and time-dependent manner. This effect was observed in primary neuronal cultures as well as in neuronal cell lines. The seeding oligomers were characterized by a distinctive lithium dodecyl sulfate-stable oligomer pattern and could be generated in a dynamic process out of pore-forming oligomers. We propose that alpha-syn oligomers form as a dynamic mixture of oligomer types with different properties and that alpha-syn oligomers can be converted into different types depending on the brain milieu conditions. Our data indicate that extracellular alpha-syn oligomers can induce intracellular alpha-syn aggregation, therefore we hypothesize that a similar mechanism might lead to alpha-syn pathology propagation.
authors.affiliation: CNS Research Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. kdanzer@partners.org
authors.forename: Karin M
authors.initials: KM
authors.lastname: Danzer
authors.forename: Simon K
authors.initials: SK
authors.lastname: Krebs
authors.forename: Michael
authors.initials: M
authors.lastname: Wolff
authors.forename: Gerald
authors.initials: G
authors.lastname: Birk
authors.forename: Bastian
authors.initials: B
authors.lastname: Hengerer
mesh_terms: D000818:Animals; D002118:Calcium / Q000378:metabolism; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000166:cytology; D004305:Dose-Response Relationship, Drug; D004622:Embryo, Mammalian; D006801:Humans; D007381:Intermediate Filament Proteins / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism* / Q000494:pharmacology*; D051379:Mice; D009154:Mutation / Q000235:genetics; D009447:Neuroblastoma / Q000473:pathology; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D010446:Peptide Fragments / Q000737:chemistry / Q000145:classification; D018709:Statistics, Nonparametric; D013997:Time Factors; D014162:Transfection / Q000379:methods
chemical_list: D007381:Intermediate Filament Proteins; D010446:Peptide Fragments; C430456:desmuslin; D002118:Calcium